Global Atopic Dermatitis (AD) Therapeutic Market: Opportunity Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018–2028)

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Global Atopic Dermatitis (AD) Therapeutic Market: Opportunity Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018–2028)

  • 216 Pages | Published On: 27-Jan-19 | Format:PDF | Last Updated: 27-Jan-19
  • GervanoRA’s Market Estimation report “Global Atopic Dermatitis (AD) Therapeutic Market: Opportunity Assessments, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2018–2028)” analyzed the current and upcoming opportunities in the Atopic Dermatitis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis industry. The report has been divided into segments like Disease Overview, Market Overview and Pipeline Analysis to provide in depth insights about the market dynamics and ongoing R&D in the Atopic Dermatitis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Atopic Dermatitis Drug Class, Route of Administration and Method of Dispensing. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Atopic Dermatitis competitive environment. We have also prognosticated the Atopic Dermatitis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
    Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
    • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
    • Estimated Pipeline Drug Approval Timelines
    • Current and Future Competitive Landscape
    • Key Company Profiles with SWOT Analysis
    • Emerging Company Profiles with Opportunity Assessments
    • Pipeline Drug Descriptions along with Development milestones (Past and Future)

  • TABLE OF CONTENTS
    1. INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. UPCOMING AND OTHER AVAILABLE REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2. EXECUTIVE SUMMARY
    2.1. MARKET SNAPSHOT, 2017-2028
    2.2. KEY EVENTS IN ATOPIC DERMATITIS COMPETITIVE SPACE
    2.3. KEY MAJOR FINDINGS
    2.3.1. DRIVERS
    2.3.2. RESTRAINTS
    2.3.3. UNMET NEEDS AND OPPORTUNITIES
    3. DISEASE OVERVIEW
    3.1. DISEASE DEFINITION AND SYMPTOMS
    3.2. DISEASE CAUSE AND DIAGNOSIS
    3.3. TREATMENT ALGORITHMS AND GUIDELINES
    3.4. EPIDEMIOLOGY AND DISEASE BURDEN
    4. MARKET DYNAMICS
    4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
    4.2. PRICING AND REIMBURSEMENT
    4.3. DEALS (MERGERS/ACQUISITIONS/ COLLABORATIONS)
    4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
    4.5. NEW DRUG APPROVAL (EX-US) SINCE 2010
    4.6. PATENT ANALYSIS (EXPIRIES AND GENERICIZATION)
    4.6.1. PATENT ANALYSIS OF APPROVED PRODUCTS
    4.6.2. PATENT ANALYSIS OF KEY PIPELINE PRODUCTS
    5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINES
    5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    5.1.1. PRE-REGISTRATION MOLECULES
    5.1.2. PHASE 3 MOLECULES
    5.1.3. PHASE 2 MOLECULES
    5.1.4. PHASE 1 MOLECULES
    5.1.5. PRECLINICAL MOLECULES
    5.1.6. EARLY R&D MOLECULES
    5.1.7. DISCONTINUED AND INACTIVE MOLECULES
    5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    5.2.1. UNMET NEEDS AND OPPORTUNITIES
    5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    5.3.1. UNMET NEEDS AND OPPORTUNITIES
    5.4. PIPELINE ANALYSIS BY DRUG CLASS
    5.4.1. UNMET NEEDS AND OPPORTUNITIES
    5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
    5.5.1. UNMET NEEDS AND OPPORTUNITIES
    5.6. ESTIMATED APPROVAL TIMELINE
    5.6.1. METHODOLOGY
    5.6.2. ESTIMATED APPROVAL TIMELINES US & EX-US
    6. GLOBAL ATOPIC DERMATITIS MARKET BY DRUG CLASS
    6.1. INTRODUCTION
    6.2. CORTICOSTEROIDS
    6.3. EMOLLIENTS/MOISTURIZERS
    6.4. PDE-4 INHIBITOR
    6.5. CALCINEURIN INHIBITORS
    6.6. BIOLOGICS
    6.7. OTHERS
    7. GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY ROUTE OF ADMINISTRATION
    7.1. INTRODUCTION
    7.2. TOPICAL
    7.3. ORAL
    7.4. INJECTABLE
    8. ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING
    8.1. INTRODUCTION
    8.2. PRESCRIPTION
    8.3. OTC
    9. GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY GEOGRAPHY
    9.1. INTRODUCTION
    9.2. US
    9.3. UK
    9.4. GERMANY
    9.5. FRANCE
    9.6. ITALY
    9.7. SPAIN
    9.8. CHINA
    9.9. JAPAN
    9.10. INDIA
    9.11. RUSSIA
    9.12. BRAZIL
    9.13. ROW
    10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
    10.1. ESTABLISHED COMPANIES
    10.1.1. SANOFI
    10.1.2. PFIZER PHARMACEUTICALS
    10.2. EMERGING COMPANIES
    10.3. KEY EMERGING COMPANY PROFILES
    10.3.1. DS BIOPHARMA LIMITED
    10.3.2. RALEXAR THERAPEUTICS INC
    10.3.3. AKAAL PHARMA PTY LTD
    10.3.4. AOBIOME, LLC
    10.3.5. MENLO THERAPEUTICS INC
    10.3.6. SPHERIUM BIOMED S.L
    10.3.7. UNION THERAPEUTICS A/S
    10.3.8. ANAPTYSBIO, INC
    10.3.9. ABEOME CORPORATION
    10.3.10. ASANA BIOSCIENCES, LLC
    11. ABBREVIATIONS

    LIST OF TABLES:

    TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
    TABLE 02: TOP 10 DEALS RANKED BY THE DEAL AMOUNT
    TABLE 03: MAJOR LICENSING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
    TABLE 04: MAJOR ACQUISITIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
    TABLE 05: MAJOR AGREEMENTS IN ATOPIC DERMATITIS THERAPEUTIC AREA
    TABLE 06: MAJOR COLLABORATIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA
    TABLE 07: MAJOR FINANCING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA
    TABLE 08: US FDA APPROVED DRUGS SINCE 2010
    TABLE 09: ATOPIC DERMATITIS APPROVED DRUGS (EX-US) SINCE 2010
    TABLE 10: DUPIXENT US AND EU PATENTS OVERVIEW
    TABLE 11: DUPIXENT PATENT EXPIRATIONS
    TABLE 12: THE U.S PATENTS OF DS BIOPHARMA LIMITED
    TABLE 13: THE U.S PATENTS OF RALEXAR THERAPEUTICS, INC.
    TABLE 14: THE U.S PATENTS OF AKAAL PHARMA PTY LTD.
    TABLE 15: THE U.S PATENTS OF AOBIOME, LLC
    TABLE 16: THE U.S PATENTS OF MENLO THERAPEUTICS INC.
    TABLE 17: ATOPIC DERMATITIS PHASE 3 MOLECULES
    TABLE 18: ATOPIC DERMATITIS PHASE 2 MOLECULES
    TABLE 19: ATOPIC DERMATITIS PHASE 1 MOLECULES
    TABLE 20: ATOPIC DERMATITIS PRECLINICAL MOLECULES
    TABLE 21: ATOPIC DERMATITIS EARLY R&D STAGE MOLECULES
    TABLE 22: ATOPIC DERMATITIS INACTIVE AND DISCONTINUED MOLECULES
    TABLE 23: ATOPIC DERMATITIS PIPELINE ANALYSIS BY TOPICAL ROA
    TABLE 24: ATOPIC DERMATITIS PIPELINE ANALYSIS BY ORAL ROA
    TABLE 25: ATOPIC DERMATITIS PIPELINE ANALYSIS BY ORAL ROA
    TABLE 26: ATOPIC DERMATITIS DRUG PIPELINE ANALYSIS, IMMUNOMODULATORS
    TABLE 27: ATOPIC DERMATITIS DRUG PIPELINE ANALYSIS, PDE4 INHIBITORS
    TABLE 28: ATOPIC DERMATITIS PIPELINE ANALYSIS, ANTI-INFLAMMATORY
    TABLE 29: ATOPIC DERMATITIS PIPELINE ANALYSIS, ANTI-MICROBIAL
    TABLE 30: ATOPIC DERMATITIS PIPELINE ANALYSIS, JAK INHIBITORS
    TABLE 31: ESTIMATED APPROVAL TIMELINES OF ATOPIC DERMATITIS PIPELINE DRUGS
    TABLE 32: GLOBAL ATOPIC DERMATITIS MARKET BY DRUG CLASS, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 33: AVAILABLE TOPICAL AND SYSTEMIC CORTICOSTEROIDS
    TABLE 34: GLOBAL CORTICOSTEROIDS MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 35: COMMERCIALLY AVAILABLE EMOLLIENTS/MOISTURIZERS
    TABLE 36: GLOBAL EMOLLIENTS/MOISTURIZERS MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 37: GLOBAL PDE4 INHIBITOR MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 38: GLOBAL CALCINEURIN INHIBITORS MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 39: GLOBAL BIOLOGICS MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 40: GLOBAL OTHER DRUGS MARKET FOR ATOPIC DERMATITIS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 41: GLOBAL ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 42: GLOBAL ATOPIC DERMATITIS MARKET FOR TOPICAL DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 43: GLOBAL ATOPIC DERMATITIS MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 44: GLOBAL ATOPIC DERMATITIS MARKET FOR INJECTATBLE DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 45: GLOBAL ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 46: GLOBAL ATOPIC DERMATITIS MARKET FOR PRESCRIPTION DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 47: GLOBAL ATOPIC DERMATITIS MARKET FOR OTC DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 48: GLOBAL ATOPIC DERMATITIS MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 49: US ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 50: US ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 51: US ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 52: UK ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 53: UK ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 54: UK ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 55: GERMANY ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 56: GERMANY ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 57: GERMANY ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 58: FRANCE ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 59: FRANCE ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 60: FRANCE ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 61 : ITALY ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 62: ITALY ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 63: ITALY ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 64: SPAIN ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 65: SPAIN ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 66: SPAIN ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 67: CHINA ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 68: CHINA ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 69: CHINA ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 70: JAPAN ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 71: JAPAN ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 72: JAPAN ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 73: INDIA ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 74: INDIA ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 75: INDIA ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 76: RUSSIA ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 77: RUSSIA ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 78: RUSSIA ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 79: BRAZIL ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 80: BRAZIL ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 81: BRAZIL ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 82: ROW ATOPIC DERMATITIS MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 83: ROW ATOPIC DERMATITIS MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)
    TABLE 84: ROW ATOPIC DERMATITIS MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)
    TABLE 85: SANOFI PRODUCT PORTFOLIO
    TABLE 86: INFLAMMATION AND IMMUNOLOGY PIPELINE PRODUCTS OF SANOFI
    TABLE 87: CARDIOVASCULAR & METABOLISM PIPELINE PRODUCTS OF SANOFI
    TABLE 88: DIABETES PIPELINE PRODUCTS OF SANOFI
    TABLE 89: MS AND NEURO PIPELINE PRODUCTS OF SANOFI
    TABLE 90: ONCOLOGY PIPELINE PRODUCTS OF SANOFI
    TABLE 91: RARE BLOOD DISORDERS PIPELINE PRODUCTS OF SANOFI
    TABLE 92: RARE DISEASES PIPELINE PRODUCTS OF SANOFI
    TABLE 93: VACCINES PIPELINE PRODUCTS OF SANOFI
    TABLE 94: R&D ACTIVITIES OF SANOFI
    TABLE 95: MILESTONES ACHIEVED BY SANOFI
    TABLE 96: CONFERENCES/EVENTS ATTENDED BY SANOFI
    TABLE 97: RECENT DEVELOPMENTS MADE BY SANOFI
    TABLE 98: PFIZER PRODUCT PORTFOLIO
    TABLE 99: PHASE 2 AND PHASE 1 PROGRAM, INFLAMMATION AND IMMUNOLOGY AREA
    TABLE 100: PHASE 2 AND PHASE 1 PROGRAM, INTERNAL MEDICINE
    TABLE 101: PHASE 2 AND PHASE 1 PROGRAM, ONCOLOGY THERAPY AREA
    TABLE 102: PRODUCTS UNDER DEVELOPMENT, RARE DISEASES
    TABLE 103: VACCINES UNDER DEVELOPMENT
    TABLE 104: BIOSIMILARS UNDER DEVELOPMENT
    TABLE 105: DRUGS UNDER DEVELOPMENT IN OTHER AREAS OF FOCUS
    TABLE 106: R&D ACTIVITIES OF PFIZER
    TABLE 107: CONFERENCES/EVENTS ATTENDED BY PFIZER
    TABLE 108: RECENT DEVELOPMENTS MADE BY PFIZER
    TABLE 109: EMERGING COMPANIES, LICENSING OR PARTNERING OPPORTUNITIES
    TABLE 110: LIST OF OTHER EMERGING COMPANIES IN ATOPIC DERMATITIS AREA
    TABLE 111: PIPELINE PRODUCTS OF DS BIOPHARMA LIMITED
    TABLE 112: THE U.S PATENTS OF DS BIOPHARMA LIMITED
    TABLE 113: R&D ACTIVITIES OF DS BIOPHARMA LIMITED
    TABLE 114: PRESENTATIONS\ CONFERENCES BY DS BIOPHARMA LIMITED
    TABLE 115: RECENT DEVELOPMENTS BY DS BIOPHARMA LIMITED
    TABLE 116: DEALS BY DS BIOPHARMA LIMITED
    TABLE 117: THE U.S PATENTS OF RALEXAR THERAPEUTICS, INC.
    TABLE 118: R&D ACTIVITIES OF RALEXAR THERAPEUTICS, INC.
    TABLE 119: MILESTONES ACHIEVED BY RALEXAR THERAPEUTICS, INC
    TABLE 120: PIPELINE PRODUCTS OF AKAAL PHARMA PTY LTD
    TABLE 121: THE U.S PATENTS OF AKAAL PHARMA PTY LTD.
    TABLE 122: R&D ACTIVITIES OF AKAAL PHARMA PTY LTD
    TABLE 123: PRESENTATIONS\ CONFERENCES BY AKAAL PHARMA PTY LTD
    TABLE 124: RECENT DEVELOPMENTS BY AKAAL PHARMA PTY LTD
    TABLE 125: PIPELINE PRODUCTS OF AOBIOME, LLC
    TABLE 126: THE U.S PATENTS OF AOBIOME, LLC
    TABLE 127: R&D ACTIVITIES OF AOBIOME, LLC
    TABLE 128: PRESENTATIONS\ CONFERENCES BY AOBIOME, LLC
    TABLE 129: RECENT DEVELOPMENTS BY AOBIOME, LLC
    TABLE 130: PIPELINE PRODUCTS OF MENLO THERAPEUTICS INC.
    TABLE 131: THE U.S PATENTS OF MENLO THERAPEUTICS INC.
    TABLE 132: R&D ACTIVITIES OF MENLO THERAPEUTICS INC.
    TABLE 133: MILESTONES ACHIEVED BY MENLO THERAPEUTICS INC.
    TABLE 134: PRESENTATIONS\ CONFERENCES BY MENLO THERAPEUTICS INC.
    TABLE 135: RECENT DEVELOPMENTS BY MENLO THERAPEUTICS INC.
    TABLE 136: PIPELINE PRODUCTS OF SPHERIUM BIOMED S.L
    TABLE 137: R&D ACTIVITIES OF SPHERIUM BIOMED S.L
    TABLE 138: PRESENTATIONS\ CONFERENCES BY SPHERIUM BIOMED S.L
    TABLE 139: RECENT DEVELOPMENTS BY SPHERIUM BIOMED S.L
    TABLE 140: PIPELINE PRODUCTS OF UNION THERAPEUTICS A/S
    TABLE 141: R&D ACTIVITIES OF UNION THERAPEUTICS A/S
    TABLE 142: PRESENTATIONS\CONFERENCES\EVENTS BY UNION THERAPEUTICS A/S
    TABLE 143: RECENT DEVELOPMENTS BY UNION THERAPEUTICS A/S
    TABLE 144: PIPELINE PRODUCTS OF ANAPTYSBIO INC.
    TABLE 145: ANTICIPATED FUTURE MILESTONES OF ANAPTYSBIO’S
    TABLE 146: R&D ACTIVITIES OF ANAPTYSBIO’S
    TABLE 147: PRESENTATIONS/ CONFERENCES BY ANAPTYSBIO’S
    TABLE 148: PIPELINE PRODUCTS OF ABEOME CORPORATION
    TABLE 149: PRESENTATIONS\ CONFERENCES BY ABEOME CORPORATION
    TABLE 150: RECENT DEVELOPMENTS OF ABEOME CORPORATION
    TABLE 151: PIPELINE PRODUCTS OF ASANA BIOSCIENCES
    TABLE 152: R&D ACTIVITIES OF ASANA BIOSCIENCES
    TABLE 153: ACHIEVED MILESTONES OF ASANA BIOSCIENCES
    TABLE 154: PRESENTATIONS\ CONFERENCES BY ASANA BIOSCIENCES

    LIST OF FIGURES:

    FIGURE 01: GLOBAL ATOPIC DERMATITIS MARKET 2017-2028: MARKET SNAPSHOT
    FIGURE 02: GLOBAL ATOPIC DERMATITIS MARKET BY GEOGRAPHY 2017 V/S 2028
    FIGURE 03: ATOPIC DERMATITISMARKET BY METHOD OF DISPENSING, 2017
    FIGURE 04: ATOPIC DERMATITISMARKET BY ROA, 2017
    FIGURE 05: KEY PIPELINE EVENTS, 2019-2034
    FIGURE 06: KEY INFLECTION POINTS, MAJOR DRUG APPROVALS
    FIGURE 07: ATOPIC DERMATITIS THERAPEUTIC AREA DEALS OVERVIEW
    FIGURE 08: ATOPIC DERMATITIS DEALS, GEOGRAPHY SPLIT-UP
    FIGURE 09: ATOPIC DERMATITIS DEALS, GEOGRAPHY V/S DEAL TYPE
    FIGURE 10: ATOPIC DERMATITIS DRUG PIPELINE 2018, HSD SPLIT
    FIGURE 11: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY GEOGRAPHY
    FIGURE 12: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY ROA
    FIGURE 13: TOPICALS BY HSD SPLIT-UP
    FIGURE 14: ORALS BY HSD SPLIT-UP
    FIGURE 15: PIPELINE ANALYSIS BY INJECTABLES, SPLIT BY TECHNIQUE USED
    FIGURE 16: INJECTABLES BY HSD SPLIT-UP
    FIGURE 17: ATOPIC DERMATITIS DRUG CLASSES SCENARIO
    FIGURE 18: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD
    FIGURE 19: JAK INHIBITORS SPLIT BY HSD
    FIGURE 20: CORTICOSTERIODS HOLD MAXIMUM SHARE IN THE ATOPIC DERMATITIS MARKET, 2018
    FIGURE 21: ATOPIC DERMATITIS DRUG MARKET, 2017 V/S 2028
    FIGURE 22: GLOBAL CORTICOSTEROIDS MARKET, 2018 V/S 2028
    FIGURE 23: GLOBAL EMOLLIENTS/MOISTURIZERS MARKET, 2018 V/S 2028
    FIGURE 24: GLOBAL PDE4 INHIBITORS MARKET, 2018 V/S 2028
    FIGURE 25: GLOBAL CALCINEURIN INHIBITORS MARKET, 2018 V/S 2028
    FIGURE 26: GLOBAL BIOLOGICS MARKET, 2018 V/S 2028
    FIGURE 27: GLOBAL OTHER DRUGS MARKET, 2018 V/S 2028
    FIGURE 28: TOPICAL ROUTE OF ADMINISTRATION IS EXPECTED TO HOLD MAXIMUM SHARE IN THE ATOPIC DERMATITIS MARKET, 2018
    FIGURE 29: GLOBAL ATOPIC DERMATITIS ROA SCENARIO, 2017
    FIGURE 30: GLOBAL TOPICAL DRUGS MARKET, 2018 V/S 2028
    FIGURE 31: GLOBAL ORALS DRUGS MARKET, 2018 V/S 2028
    FIGURE 32: GLOBAL INJECTABLES DRUGS MARKET, 2018 V/S 2028
    FIGURE 33: PRESCRIPTION SEGMENT IS EXPECTED TO HOLD MAXIMUM SHARE IN THE ATOPIC DERMATITIS MARKET, 2018
    FIGURE 34: GLOBAL ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2017
    FIGURE 35: GLOBAL PRESCRIPTION MARKET, 2018 V/S 2028
    FIGURE 36: GLOBAL PRESCRIPTION MARKET, 2018 V/S 2028
    FIGURE 37: GLOBAL ATOPIC DERMATITIC MARKET SPLIT BY 11 MM, 2018 V/S 2028
    FIGURE 38: GLOBAL ATOPIC DERMATITIC MARKET SPLIT BY 11 MM, 2018
    FIGURE 39: US DRUG CLASS MARKET SPLIT, 2018
    FIGURE 40: US ROA MARKET SPLIT, 2018
    FIGURE 41: US MARKET FOR METHOD OF DISPENSING, 2018
    FIGURE 42: UK DRUG CLASS MARKET SPLIT, 2018
    FIGURE 43: UK ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 44: UK MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
    FIGURE 45: GERMANY DRUG CLASS MARKET, 2018 V/S 2028
    FIGURE 46: GERMANY ROA MARKET SPLIT, 2028
    FIGURE 47: GERMANY MARKET FOR METHOD OF DISPENSING, 2028
    FIGURE 48: FRANCE DRUG CLASS MARKET SPLIT, 2018
    FIGURE 49: FRANCE ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 50: FRANCE MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
    FIGURE 51: ITALY DRUG CLASS MARKET, 2018 V/S 2028
    FIGURE 52: ITALY ROA MARKET SPLIT, 2018
    FIGURE 53: ITALY MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
    FIGURE 54: SPAIN DRUG CLASS MARKET SPLIT, 2018
    FIGURE 55: SPAIN ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 56: SPAIN MARKET FOR METHOD OF DISPENSING, 2018
    FIGURE 57: CHINA DRUG CLASS MARKET SPLIT, 2018 V/S 2028
    FIGURE 58: CHINA ROA MARKET SPLIT, 2028
    FIGURE 59: CHINA MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
    FIGURE 60: JAPAN DRUG CLASS MARKET SPLIT, 2018
    FIGURE 61: JAPAN ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 62: JAPAN MARKET FOR METHOD OF DISPENSING, 2028
    FIGURE 63: INDIA DRUG CLASS MARKET SPLIT, 2018 V/S 2028
    FIGURE 64: INDIA ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 65: INDIA MARKET FOR METHOD OF DISPENSING, 2028 V/S 2028
    FIGURE 66: RUSSIA DRUG CLASS MARKET SPLIT, 2028
    FIGURE 67: RUSSIA ROA MARKET SPLIT, 2028
    FIGURE 68: RUSSIA MARKET FOR METHOD OF DISPENSING, 2028
    FIGURE 69: BRAZIL DRUG CLASS MARKET SPLIT, 2018 V/S 2028
    FIGURE 70: BRAZIL ROA MARKET SPLIT, 2018 V/S 2028
    FIGURE 71: BRAZIL MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028
    FIGURE 72: FINANCIAL INFORMATION OF SANOFI BY HEALTHCARE AREA (IN %)
    FIGURE 73: FINANCIAL INFORMATION OF SANOFI BY GEOGRAPHICAL AREA (IN %)
    FIGURE 74: SWOT ANALYSIS OF SANOFI
    FIGURE 75: FINANCIAL INFORMATION OF PFIZER
    FIGURE 76: SWOT ANALYSIS OF PFIZER

Pricing

Individual Pricing $3500

Corporate Pricing $3500

Enterprise Pricing $3500

(We are offering all the above license types for a single price!!)